Policies for replacing long-term indwelling urinary catheters in adults

We would also like to thank the foll owing Cochrane Incontinence editorial base staff members for their help and support with this re-view: Cathryn Glazener, Sheila Wallace, Mandy Fader, Peter Her-bison and Suzanne Macdonald. The review authors are grateful to Toby Lasseron for his advice. The review authors are thankful to Dr Beverly Priefer for responding to our query about Priefer 1982. Policies for replacing long‐term indwelling urinary catheters in adults, Protocol, Fergus PM Cooper, Cameron Edwin Alexander, Sanjay Sinha, Muhammad Imran Omar; https://doi.org/10.1002/14651858.CD011115; 14 May 2014Peer reviewedPublisher PD

Conservative interventions for managing urinary incontinence after prostate surgery

Peer reviewedPublisher PD

Reply to Qingpeng Xie and Dianqiu Shen s Letter to the Editor re: Bhavan P. Rai, Jos Luis Dominguez Escrig, Lu s Vale, et al. Systematic Review of the Incidence of and Risk Factors for Urothelial Cancers and Renal Cell Carcinoma Among Patients with Haematuria. Eur Urol 2022;82:182-92

Peer reviewedPostprin

The impact of low-pressure pneumoperitoneum on robotic-assisted radical cystectomy and intracorporeal ileal conduit urinary diversion : A case-control study.

Peer reviewedPublisher PD

Conservative interventions for managing urinary incontinence after prostate surgery

Acknowledgements: We would like to thank Sheila Wallace, Lindsey Elstub, Nicole O'Connor and Claire Eastaugh for their editorial support on this review. We are grateful to the following people for assisting with translations for the review:• Gabriela Azevedo Sansoni: Faculty of Medicine and Surgery, University of Milan• Yuan Chi: Health Network, China; Cochrane Campbell Global Ageing Partnership, UK • Elaine Martí • Benjamin Hernández Wolters: Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Mexico • Fangfang Zhao: Chinese Journal of Integrated Traditional and Western Medicine, China; Xiyuan Hospital, Chinese Academy of Chinese Medical Sciences, China Editorial and peer-reviewer contributions The following people conducted the editorial process for this article. • Sign-oH Editor (final editorial decision): Luke Vale, Cochrane's editorial board. • Managing Editor (selected peer reviewers, collated peer-reviewer comments, provided editorial guidance to authors, edited the article): Samuel Hinsley, Central Editorial Service • Editorial Assistant (conducted editorial policy checks and supported editorial team): Leticia Rodrigues, Central Editorial Service • Copy Editor (copy editing and production): Heather Maxwell • Peer-reviewers (provided comments and recommended an editorial decision): Dr. M.S. Rahnama'i st. Elisabeth - Tweesteden Hospital Tilburg - The Netherlands (clinical review), Akhil Das, MD FACS, University of California Irvine (clinical review), Brian Duncan (consumer review), Nuala Livingstone, Cochrane Evidence Production and Methods Directorate (methods review), Anne Littlewood, Cochrane Oral Health (search review). 1 of additional peer reviewers provided clinical peer review but chose not to be publicly acknowledged. Funding Information: Dr Moore's studies were funded for 4 years by a Doctoral Fellowship from the Kidney Foundation of Canada. Funding for the research project was received from the Oncology Nurses' Society, Canadian Nurses' Foundation, Caritas Health, Alberta Physiotherapy Association, Edna Minton Foundation, and the University of Edmonton, Canada This study was supported by grant R01 DK60044 from the National Institute of Diabetes and Digestive and Kidney Diseases and by the Department of Veterans Affairs Birmingham–Atlanta Geriatric Research, Education, and Clinical Center. We would like to thank the National Science Council Grant of Taiwan for financial support (NSC 96-2314-B-214-007; NSC 97-2314-B-214-009-MY2). Four studies stated that they did not receive any funding, while seven were funded solely by governmental organisations and one solely by a foundation. One study was funded by a governmental organisation and a university, one by a charity and a university and one through both charity and a pharmaceutical company. Ten studies did not report where they had obtained funding for their study. Supported by Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP), 2003/07656-7. This study received financial support from the National Council for Scientific and Technological Development (CNPq) through scientific research grant to the author This study was funded by the Foundation for Research Support of the State of São Paulo (FAPESP), under registration number 2011/12154-7. This study was supported by a grant from the Fund of Scientific Research, Flanders, Belgium Funded by the Alberta Heritage Foundation for Medical Research, the Northern Alberta Urology Foundation, and Pfizer Corporation (unrestricted). Scientific Research Foundation of Zhuhai Science and Technology Industry and Trade Bureau, No.2012D0401990028 Conflicts of interest: Quote: "All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Goode reported receiving a research grant from Pfizer. Dr Bur-gio reported serving on the advisory board of Astellas, as a consultant to GlaxoSmithKline, and as receiving research grants and serving as a consultant to Pfizer. Dr Johnson reported receiving grant support from Astellas, Pfizer and Vantia and serving as a consultant for Boehringer-Ingelheim, Ferring, Johnson & Johnson, Pfizer, and Vantia. Dr Issa reported serving as a consultant for and on the speakers bureau and receiving honoraria from GlaxoSmithKline. Dr Lloyd reported receiving research support from Allergan, Indevus, and Pfizer; serving as a consultant to and on the speakers bureau of Astellas, Boehringer-Ingelheim, GlaxoSmithKline, Novartis, and Pfizer. No other authors reported having a financial conflict of interest" Publisher Copyright: Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.Peer reviewe

Association of Type D personality with cardiovascular disease and its prognosis

Objective: To evaluate the association of Type D personality with cardiovascular disease and its prognosis. Methodology: This cross sectional study study was conducted in cardiology department of MBBS medical college Mirpur, from February 2019 to February 2020 in a period of one year. A total of 281 patients with cardiovascular diseases were included. Demographic information and risk factors were noted. Screening for metabolic syndrome was done using international diabetes federation criteria based upon central obesity. The assessment of type D personality was made through DS-14, type D scale, which is the most widely used instrument for type D personality measurement. In which all the 14 items are score on a 5-point Likert scale. Results: There were 77 (27.40%) patients having type D personality, with significantly less mean age (45.36 ± 6.2 vs. 53.45 ± 9.6) in comparison to patients without type D personality. No significant (p-value > 0.05) difference was noted in gender, education, occupation and marital status of the patients having type D personality. The rate of diabetes mellitus (44.46% vs. 37.25%), hypertension (59.74% vs. 47.06%), smoking status (62.34% vs. 53.43%) and metabolic syndrome (48.05% vs. 40.69%) were similar in both groups. The mean values of systolic (124.53 ± 12.35 vs. 116.28 ± 14.30, p-value = 0.000) and diastolic (78.44 ± 6.92 vs. 74.62 ± 7.48, p-value = 0.0001) blood pressure were significantly higher in patients having type D personality. Conclusions: A considerable number of cardiac patients in our study had type D personality trait. This trait was more common in younger age and male patients showing raised levels of blood pressure and HDL cholesterol. Key words: Cardiovascular disease, Type D personality, low HDL cholesterol, Prognosi

Making the GRADE : Providing Clinical Practice Guidance to the European Association of Urology

Peer reviewe